CLINICAL_TRIALS
trial_result
· 2019-02-01
Clinical Trial Update: Study Of 323U66 SR In Major Depressive Disorder [Phase 2]
Summary
Phase 2 study of 323U66 SR in major depressive disorder has completed, and results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: GlaxoSmithKline | Conditions: Depressive Disorder | Phase 2 | Status: COMPLETED | Results posted: 2019-02-01